PostEra

Merck KGaA Buys PostEra’s Oral Fertility Molecules

Merck KGaA has acquired PostEra’s two oral fertility molecule programs in a deal worth mid-double-digit millions. This move capitalizes on PostEra's recent strategic shift toward developing drug candi